198 related articles for article (PubMed ID: 36871279)
1. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat.
Girerd N; Zannad F
J Intern Med; 2023 May; 293(5):550-558. PubMed ID: 36871279
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
3. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
4. SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
Requena-Ibáñez JA; Santos-Gallego CG; Badimón JJ
Rev Esp Cardiol (Engl Ed); 2022 Oct; 75(10):833-841. PubMed ID: 35817327
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
Frampton JE
Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
8. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
9. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
10. Expanded use of sodium-glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction.
Schoenborn EM; Skersick PT; Thrasher CM; Page RL
Pharmacotherapy; 2023 Sep; 43(9):950-962. PubMed ID: 37323057
[TBL] [Abstract][Full Text] [Related]
11. Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Ortega-Paz L; Cristóbal H; Ortiz-Perez JT; García de Frutos P; Mendieta G; Sandoval E; Rodriguez JJ; Ortega E; García-Álvarez A; Brugaletta S; Sabaté M; Dantas AP
ESC Heart Fail; 2023 Feb; 10(1):453-464. PubMed ID: 36303443
[TBL] [Abstract][Full Text] [Related]
12. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
Gonzalez J; Dave CV
BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
[TBL] [Abstract][Full Text] [Related]
13. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
[TBL] [Abstract][Full Text] [Related]
14. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection.
Rastogi T; Girerd N
Heart Fail Clin; 2022 Oct; 18(4):561-577. PubMed ID: 36216486
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibitors in acute heart failure: real-world prescription trends and outcomes analysis.
Mizobuchi S; Saito Y; Kitano D; Toyama K; Miyagawa M; Koyama Y; Fujito H; Kojima K; Murata N; Fukamachi D; Okumura Y
ESC Heart Fail; 2024 Feb; 11(1):410-421. PubMed ID: 38017700
[TBL] [Abstract][Full Text] [Related]
19. Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds" Approach?
Zhang Q; Kang Y; Tang S; Yu CM
Curr Cardiol Rep; 2021 Oct; 23(11):171. PubMed ID: 34647188
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
